Shots:

• The P-IIIb (BATURA) study is assessing inhaled Airsupra (180mcg/160mcg) vs albuterol (180mcg) as-needed rescue medication for 12mos. in patients (≥12yrs.) with intermittent or mild persistent asthma. Subjects were on as-needed SABA alone or with low-dose ICS/LTRA maintenance therapy
• Study achieved its 1EP, showing reduced risk of severe exacerbation in response to symptoms, with safety & tolerability aligning with the known profiles. Results to be shared with health authorities & highlighted at ACAAI 2024
• Airsupra (developed with Avillion) is approved in the US to prevent bronchoconstriction & reduce exacerbations risk in asthmatic patients (≥18yrs.). It is being developed in P-III trials for adolescents (ACADIA) & Chinese patients (BAIYUN

Ref: Astrazeneca | Image: Astrazeneca

Related News:- AstraZeneca Reports the US FDA’s sNDA Acceptance of Calquence with Priority Review for Mantle Cell Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com